908 Devices Inc. (NASDAQ:MASS) Forecasted to Post Q1 2025 Earnings of ($0.31) Per Share

908 Devices Inc. (NASDAQ:MASS - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for 908 Devices in a research note issued on Tuesday, April 30th. Leerink Partnrs analyst P. Souda expects that the company will post earnings per share of ($0.31) for the quarter. The consensus estimate for 908 Devices' current full-year earnings is ($1.27) per share. Leerink Partnrs also issued estimates for 908 Devices' Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.19) EPS and Q4 2025 earnings at ($0.16) EPS.

908 Devices (NASDAQ:MASS - Get Free Report) last posted its quarterly earnings results on Tuesday, April 30th. The company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.36) by $0.03. 908 Devices had a negative net margin of 68.57% and a negative return on equity of 20.47%. The company had revenue of $9.99 million during the quarter, compared to analyst estimates of $9.29 million. During the same period in the prior year, the business posted ($0.39) EPS. The firm's revenue was up 5.3% compared to the same quarter last year.

908 Devices Stock Down 0.2 %

Shares of NASDAQ:MASS traded down $0.01 during midday trading on Thursday, reaching $5.67. The company's stock had a trading volume of 311,882 shares, compared to its average volume of 176,785. The firm has a 50 day moving average of $6.57 and a 200-day moving average of $7.07. The firm has a market capitalization of $187.00 million, a P/E ratio of -5.20 and a beta of 1.02. 908 Devices has a 12-month low of $4.85 and a 12-month high of $12.51.

Hedge Funds Weigh In On 908 Devices

Hedge funds and other institutional investors have recently bought and sold shares of the stock. ARK Investment Management LLC grew its holdings in shares of 908 Devices by 8.3% in the fourth quarter. ARK Investment Management LLC now owns 4,346,579 shares of the company's stock valued at $48,769,000 after purchasing an additional 333,119 shares in the last quarter. Granahan Investment Management LLC lifted its position in shares of 908 Devices by 10.6% during the fourth quarter. Granahan Investment Management LLC now owns 2,038,658 shares of the company's stock valued at $22,874,000 after buying an additional 195,368 shares during the last quarter. Iron Triangle Partners LP lifted its position in shares of 908 Devices by 31.1% during the fourth quarter. Iron Triangle Partners LP now owns 1,284,947 shares of the company's stock valued at $14,417,000 after buying an additional 304,484 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its holdings in shares of 908 Devices by 3.0% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 629,994 shares of the company's stock valued at $4,196,000 after acquiring an additional 18,492 shares in the last quarter. Finally, AWM Investment Company Inc. acquired a new position in 908 Devices in the 3rd quarter worth approximately $3,740,000. Institutional investors own 88.06% of the company's stock.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.